Physician profile
Robert Keith Mcafee
NPI 1689777880
$1,097.75
in general payments reported to CMS, 2019-2025
19 companies · $268 in 2025
The $268 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.64 · 2023: $380 · 2024: $428 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $168.34 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $148.59 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Hologic Sales and Service, LLC | $116.28 | 2023-2025 | Aptima |
| Abbvie INC. | $81.34 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.82 | 2023-2025 | |
| Pfizer INC. | $63.76 | 2023-2025 | |
| Dexcom, INC. | $63.53 | 2024-2025 | Dexcom G6 Transmitter |
| Alk-Abello, INC | $50.54 | 2024 | Grastek, Odactra |
| Indivior INC. | $42.23 | 2023-2024 | Sublocade |
| Glaxosmithkline, LLC. | $41.88 | 2023 | Arexvy, Shingrix |
| Exact Sciences Corporation | $37.67 | 2023-2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $37.11 | 2023 | Dificid, Pneumovax 23, Gardasil 9 |
| Viiv Healthcare Company | $32.89 | 2025 | Apretude |
| Gilead Sciences, INC. | $32.18 | 2024 | Descovy |
| Sage Therapeutics, LLC | $24.01 | 2025 | Zurzuvae |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $21.64 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.53 | 2023 | Xifaxan |
| Agios Pharmaceuticals, INC. | $20.44 | 2024 | Pyrukynd |
| Amneal Pharmaceuticals LLC | $15.97 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcafee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.